Literature DB >> 15319782

Monogenic X-linked mental retardation: is it as frequent as currently estimated? The paradox of the ARX (Aristaless X) mutations.

Jean-Louis Mandel1, Jamel Chelly.   

Abstract

Mental retardation affects 30 to 50% more males than females, and X-linked mental retardation (XLMR) is thought to account for the major part of this sex bias. Nonsyndromic XLMR is very heterogeneous, with more than 15 genes identified to date, each of them accounting for a very small proportion of nonsyndromic families. The Aristaless X (ARX) gene is an exception since it was found mutated in 11 of 136 such families, with a highly recurrent mutation (dup24) leading to an expansion of a polyalanine tract in the protein. The rather high frequency of dup24 reported in families with clear X-linked MR (6.6%) contrasts with the very low prevalence of this mutation observed in sporadic male MR (0.13%). We conclude that monogenic XLMR has much lower prevalence in male MR (< 10%) than the 23% that would be required to account for a 30% male excess of mental retardation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15319782     DOI: 10.1038/sj.ejhg.5201247

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  28 in total

1.  Comparative frequency of fragile-X (FMR1) and creatine transporter (SLC6A8) mutations in X-linked mental retardation.

Authors:  J L Mandel
Journal:  Am J Hum Genet       Date:  2004-10       Impact factor: 11.025

Review 2.  X linked mental retardation: a clinical guide.

Authors:  F L Raymond
Journal:  J Med Genet       Date:  2005-08-23       Impact factor: 6.318

3.  Familial West syndrome and dystonia caused by an Aristaless related homeobox gene mutation.

Authors:  Gabriele Wohlrab; Goekhan Uyanik; Claudia Gross; Ute Hehr; Jürgen Winkler; Bernhard Schmitt; Eugen Boltshauser
Journal:  Eur J Pediatr       Date:  2005-02-22       Impact factor: 3.183

4.  Screening of ARX in mental retardation families: Consequences for the strategy of molecular diagnosis.

Authors:  K Poirier; D Lacombe; B Gilbert-Dussardier; M Raynaud; V Desportes; A P M de Brouwer; C Moraine; J P Fryns; H H Ropers; C Beldjord; J Chelly; T Bienvenu
Journal:  Neurogenetics       Date:  2005-10-19       Impact factor: 2.660

5.  AGTR2 in brain development and function.

Authors:  Virginie S Vervoort; Greagory Guzauskas; John Archie; Charles E Schwartz; Roger E Stevenson; Anand K Srivastava
Journal:  Am J Med Genet A       Date:  2006-03-01       Impact factor: 2.802

6.  Brain volume reductions within multiple cognitive systems in male preterm children at age twelve.

Authors:  Shelli R Kesler; Allan L Reiss; Betty Vohr; Christa Watson; Karen C Schneider; Karol H Katz; Jill Maller-Kesselman; John Silbereis; R Todd Constable; Robert W Makuch; Laura R Ment
Journal:  J Pediatr       Date:  2007-11-05       Impact factor: 4.406

Review 7.  Rho-linked genes and neurological disorders.

Authors:  Nael Nadif Kasri; Linda Van Aelst
Journal:  Pflugers Arch       Date:  2007-11-15       Impact factor: 3.657

8.  X-linked creatine transporter (SLC6A8) mutations in about 1% of males with mental retardation of unknown etiology.

Authors:  Amy J Clark; Efraim H Rosenberg; Ligia S Almeida; Tim C Wood; Cornelis Jakobs; Roger E Stevenson; Charles E Schwartz; Gajja S Salomons
Journal:  Hum Genet       Date:  2006-04-26       Impact factor: 4.132

9.  A higher mutational burden in females supports a "female protective model" in neurodevelopmental disorders.

Authors:  Sébastien Jacquemont; Bradley P Coe; Micha Hersch; Michael H Duyzend; Niklas Krumm; Sven Bergmann; Jacques S Beckmann; Jill A Rosenfeld; Evan E Eichler
Journal:  Am J Hum Genet       Date:  2014-02-27       Impact factor: 11.025

10.  A new chromosome x exon-specific microarray platform for screening of patients with X-linked disorders.

Authors:  Stavros Bashiardes; Ludmila Kousoulidou; Hans van Bokhoven; Hans-Hilger Ropers; Jamel Chelly; Claude Moraine; Arjan P M de Brouwer; Hilde Van Esch; Guy Froyen; Philippos C Patsalis
Journal:  J Mol Diagn       Date:  2009-09-24       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.